Falk Gastro Info 5-6/2015

Video

Video course abdominal ultrasound

Ileocecal region, appendix

Author: Prof. Dr. Christoph F. Dietrich, Caritas Krankenhaus Bad Mergentheim.

Please switch on your loudspeakers!

Link to Falk Mediacenter:

http://media.falkfoundation.de/index.php?id=155&L=1&tx_mediacenter_pi1[uid]=403&tx_mediacenter_pi1[typ]=v&cHash=1b3b24e4e3ab873d010c2e81ebde9899

Link to the video directly:

http://media.drfalkpharma.de/fileadmin/media/46_Gastro_Ileocaecal_region_appendix_ENG.mp4

Video course abdominal ultrasound

Liver hilum: The use of colour Doppler imaging

Author: Prof. Dr. Christoph F. Dietrich, Caritas Krankenhaus Bad Mergentheim.

Please switch on your loudspeakers!

Link to Falk Mediacenter:

http://media.falkfoundation.de/index.php?id=118&L=1

Link to the video directly:

http://media.drfalkpharma.de/fileadmin/media/03_Liver_Liver_hilum_use_of_colour_Doppler_imaging_ENG.mp4

Bowel

Text:

Waehrens R et al, Gut. 2015;64(2):215–21

The increased irritable bowel syndrome risk among first-degree relatives and also second-degree and third-degree relatives indicates a genetic component of the familial clustering of irritable bowel syndrome.

Link:

http://www.drfalkpharma.de/index.php?L=1&id=20370#28989

Text:

Ford AC et al, Am J Gastroenterol. 2014;109(10):1547–61

Probiotics are effective treatments for irritable bowel syndrome, although which individual species and strains are the most beneficial remains unclear.

Link:

http://www.drfalkpharma.de/index.php?L=1&id=20370#c28990

Text:

Youngster I et al, JAMA. 2014;312(17):1772–8

Oral capsulized frozen fecal microbiota is safe and effective to treat relapsing Clostridium difficile infection which may greatly facilitate fecal microbiota transplantation.

Link:

http://www.drfalkpharma.de/index.php?L=1&id=20370#c28991

Text:

Lee CG et al, Am J Gastroenterol. 2015;110(2):310–9

Visceral adiposity as measured by visceral adipose tissue, but not subcutaneous adipose tissue, is associated with an increased risk of irritable bowel syndrome, especially of diarrhea-predominant irritable bowel syndrome.

Link:

http://www.drfalkpharma.de/index.php?L=1&id=20369#28836

Text:

Dhalwani NN et al, Gastroenterology. 2014;147(6):1267–74.e1

Although previous reports suggest that celiac disease may affect fertility, women with celiac disease did not have a greater likelihood of clinically recorded fertility problems than women without celiac disease in this large British population-based study.

Link:

http://www.drfalkpharma.de/index.php?L=1&id=20369#c28835

Text:

Raskin JB et al, Gastroenterology. 2014;147(4):793–802

Mesalamine was not superior to placebo in preventing recurrent diverticulitis in two related phase III trials involving 1182 patients. Mesalamine is therefore not recommended for this indication.

Link:

http://www.drfalkpharma.de/index.php?L=1&id=20369#c28834

Liver
Biliary Tracts

Text:

Bardou-Jacquet E et al, J Hepatol. 2015;62(3):682–9

Patients with mild HFE hemochromatosis benefit from adequate therapy – due to a decreased cardiovascular and extrahepatic cancer-related mortality, they have an even reduced overall mortality compared to the general population.

Link:

http://www.drfalkpharma.de/index.php?L=1&id=20370#c28992

Text:

Njei B et al, Hepatology. 2015;61(1):191–9

Current U.S. population data indicate that the peak of the HCC epidemic may be near. In the last 4 decades, survival of HCC patients has already improved significantly.

Link:

http://www.drfalkpharma.de/index.php?L=1&id=20370#c28993

Text:

Nery F et al, Hepatology. 2015;61(2):660–7

In patients with liver cirrhosis, portal vein thrombosis is associated with severity of liver disease at baseline; portal vein thrombosis is however not responsible for further progression of liver disease.

Link:

http://www.drfalkpharma.de/index.php?L=1&id=20370#c28994

Text:

Yoshida EM et al, Hepatology. 2015;61(1):41–5

The sustained virological response to sofosbuvir-based antiviral regimens against hepatitis C virus can be predicted 12 weeks after end of therapy and does not require further assessment 24 weeks after end of therapy.

Link:

http://www.drfalkpharma.de/index.php?L=1&id=20369#c28833

Text:

Bettinger D et al, Aliment Pharmacol Ther. 2015;41(1):126–36

Transjugular intrahepatic portosystemic stent shunt (TIPSS) for treating portal hypertension is safe and efficient even in patients with hepatocellular carcinoma (HCC).

Link:

http://www.drfalkpharma.de/index.php?L=1&id=20369#c28832

Text:

Hartl J et al, J Hepatol. 2015;62(3):642–6

In patients with autoimmune hepatitis and biochemical remission under immunosuppression, ALT and IgG levels within the low normal range may predict sustained remission after immunosuppression withdrawal.

Link:

http://www.drfalkpharma.de/index.php?L=1&id=20369#c28831

Oesophagus

Stomach

Duodenum

Text:

Konda VJA et al, Clin Gastroenterol Hepatol. 2014;12(12):2002–10.e1–2

For patients with Barrett’s esophagus with high-grade dysplasia or neoplasia, complete endoscopic mucosal resection is an effective and durable treatment and is a relatively safe technique. Esophageal strictures are common complications of this approach.

Link:

http://www.drfalkpharma.de/index.php?L=1&id=20370#c28995

Text:

Nasrollah L et al, Clin Gastroenterol Hepatol. 2015;13(1):94–9

Naps are associated with significantly greater esophageal acid exposure and symptoms compared with nocturnal sleep. Naps therefore might have important effects on the severity of GERD.

Link:

http://www.drfalkpharma.de/index.php?L=1&id=20370#c28996

Text:

Atluri DK et al, Aliment Pharmacol Ther. 2015;41(2):167–76

Selective serotonin reuptake inhibitors are not superior to placebo in improving chest pain or depression symptoms in patients with non-cardiac chest pain.

Link:

http://www.drfalkpharma.de/index.php?L=1&id=20370#c28997

Text:

Shakhatreh MH et al, Am J Gastroenterol. 2014;109(12):1862–8

The incidence of esophageal adenocarcinoma may be lower than previous estimated. Almost half of the esophageal adenocarcinoma cases were diagnosed within 1 year of their Barrett’s esophagus index date.

Link:

http://www.drfalkpharma.de/index.php?L=1&id=20369#c28830

Text:

Bhat SK et al, Gut. 2015;64(1):20–5

The proportion of esophageal adenocarcinoma patients with a prior diagnosis of Barrett’s esophagus is low. However, prior identification of Barrett’s esophagus is associated with improved survival.

Link:

http://www.drfalkpharma.de/index.php?L=1&id=20369#c28829

Text:

Jiang HY et al, Clin Gastroenterol Hepatol. 2015;13(1):42–50.e3

Selective serotonin reuptake inhibitor use is associated with an 1.5-fold increase in the risk of developing upper gastrointestinal bleeding.

Link:

http://www.drfalkpharma.de/index.php?L=1&id=20369#c28828

Pancreas

Text:

Bakker OJ et al, N Engl J Med. 2014;371(21):1983–93

This trial did not show the superiority of early nasoenteric tube feeding, as compared with an oral diet after 72 hours, in reducing the rate of infection or death in patients with acute pancreatitis at high risk for complications.

Link:

http://www.drfalkpharma.de/index.php?L=1&id=20370#c28998

Text:

Wu BU et al, Gut. 2015;64(1):133–8

Although simvastatin therapy has previously been linked with acute pancreatitis, it was associated with a rather reduced risk of acute pancreatitis in this large population-based retrospective study.

Link:

http://www.drfalkpharma.de/index.php?L=1&id=20369#c28827

Current Falk literature:

Ursofalk®

Now also licensed for hepatobiliary disorders in cystic fibrosis

(6 pages)

U16e

Picture:

http://www.drfalkpharma.de/fileadmin/media/Falk_Broschueren/Diagnostik_und_Therapie/Titelblatt/U16e_1-4-15.jpg

PDF:

http://www.drfalkpharma.de/fileadmin/media/Falk_Broschueren/Diagnostik_und_Therapie/PDF/U16e_1-4-15.pdf

Order by email (Please replace text by your email address):